The efficacy and tolerability of tolterodine ER Vs .
A recent meta- analysis evaluating tolterodine in comparison with other antimuscarinic drugs demonstrated that tolterodine ER was significantly more effective than placebo in reducing micturition/24 h , urinary leakage episodes/24 h , urgency episodes/24 h , and urgency incontinence episodes/24 h. With regard to adverse events , tolterodine ER was associated with a good adverse event profile result ing in the third most favorable antimuscarinic .
Conclusion Tolterodine ER result ed effective in reducing frequency urgency and nocturia and urinary leakage in male patients with OAB/storage LUTS .
Dry mouth and constipation are the most frequently reported adverse events
Background Overactive bladder (OAB)/ storage lower urinary tract symptoms ( LUTS ) have a high prevalence affecting up to 90 % of men over 80 years .
The role of sufficient therapies appears crucial .
In the present review , we analyzed the mechanism of action of tolterodine extended-release ( ER ) with the aim to clarify its efficacy and safety profile , as compared to other active treatments of OAB/storage LUTS .
Antimuscarinic drugs are the mainstay of pharmacological therapy for OAB / storage LUTS ; several studies have demonstrated that tolterodine ER is an effective and well tolerated formulation of this class of treatment .
Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
OBJECTIVE To determine the efficacy , tolerability , and safety of fesoterodine in subjects with overactive bladder ( OAB ) . METHODS This was a multicentre , r and omised , double-blind , placebo- and active-controlled trial with tolterodine extended release ( ER ) to assess the efficacy and safety of fesoterodine .  Eligible subjects ( > or = 18 yr ) with increased micturition frequency and urgency and /or urgency urinary incontinence ( UUI ) were r and omised to placebo , fesoterodine 4 mg , fesoterodine 8 mg , or tolterodine ER 4 mg for 12 wk . The primary efficacy variable was a change from baseline to week 12 in micturitions per 24 h. Co- primary end points included change from baseline to week 12 in UUI episodes per 24 h and Treatment Response ( " yes " or " no , " based on four-point treatment benefit scale ) . Secondary efficacy variables included mean volume voided per micturition , continent days per week , and number of urgency episodes . RESULTS At the end of treatment , subjects taking fesoterodine 4 and 8 mg had significant ( p<0.05 ) and clinical ly relevant improvements versus placebo in the primary , co- primary , and most secondary efficacy variables .  Tolterodine ER ( active control ) also provided significantly greater improvement than placebo for most efficacy variables , confirming the sensitivity of the study design . A more pronounced effect was observed with fesoterodine 8 mg at most end points . CONCLUSIONS Both doses of fesoterodine were significantly better than placebo in improving the symptoms of OAB and produced a significantly greater Treatment Response versus placebo .  Efficacy was more pronounced with fesoterodine 8 mg compared with the other treatments . Active treatments were well tolerated
The efficacy and tolerability of tolterodine ER Vs .
A recent meta- analysis evaluating tolterodine in comparison with other antimuscarinic drugs demonstrated that tolterodine ER was significantly more effective than placebo in reducing micturition/24 h , urinary leakage episodes/24 h , urgency episodes/24 h , and urgency incontinence episodes/24 h. With regard to adverse events , tolterodine ER was associated with a good adverse event profile result ing in the third most favorable antimuscarinic .
Conclusion Tolterodine ER result ed effective in reducing frequency urgency and nocturia and urinary leakage in male patients with OAB/storage LUTS .
Dry mouth and constipation are the most frequently reported adverse events
Background Overactive bladder (OAB)/ storage lower urinary tract symptoms ( LUTS ) have a high prevalence affecting up to 90 % of men over 80 years .
The role of sufficient therapies appears crucial .
In the present review , we analyzed the mechanism of action of tolterodine extended-release ( ER ) with the aim to clarify its efficacy and safety profile , as compared to other active treatments of OAB/storage LUTS .
Antimuscarinic drugs are the mainstay of pharmacological therapy for OAB / storage LUTS ; several studies have demonstrated that tolterodine ER is an effective and well tolerated formulation of this class of treatment .